arcadiamedicine.comCrawled Nov 3, 2026
Team CEO and Founder Nikita Obidin President and CDO Dean Carson VP of Regulatory Affairs Gary Riordan Chief of Staff Jaclyn Chau Head of Strategy and Ops Serena Lim-Strutt QA Partner Juan Gonzalez CMC Consultant Bharat Mehta Strategic Advisor Quintin Frerichs Strategic Advisor Jamie Heywood Strategic Advisor Sarah Sclarsic Scientific Advisor Boris Heifets Scientific Advisor […]
Arcadia Medicine develops safe and effective mental health therapies using empathogens to transform mental health treatment.
Sam Altman has joined Arcadia, a developer focused on advancing MDMA-assisted therapies. Arcadia aims to accelerate the clinical and regulatory progress of MDMA for mental health treatments, building on prior breakthroughs like MAPS’ (now Lykos Therapeutics) FDA Breakthrough Therapy Designation for PTSD in 2017. The involvement of a high-profile figure like Altman may amplify funding, expertise, and industry attention for MDMA-based therapies.
Oct 2025Psychedelic HealthNews article
A company receives FDA approval to conduct clinical trials for MDMA-assisted therapy. The firm is backed by Sam Altman, co-founder of OpenAI. The trials aim to explore MDMA’s potential in treating mental health conditions under controlled medical settings.
Oct 2025The IndependentNews article
Arcadia Medicine is preparing to begin clinical trials for a safer MDMA formulation to treat anxiety disorders. The company has secured backing from prominent tech founders, including Sam Altman, Coinbase co-founder Fred Ehrsam, and Figma co-founder Dylan Field. This initiative aims to explore MDMA’s therapeutic potential under controlled conditions.
Oct 2025San Francisco Business TimesNews article
Arcadia Medicine receives FDA clearance for its Investigational New Drug (IND) application, enabling the company to begin clinical trials of **AM-1002**, a patented, non-racemic form of MDMA. The trial aims to explore its potential as a safer empathogen for treating mental health disorders. Arcadia specializes in developing novel compounds for psychiatric applications.
Oct 2025BioSpaceNews article